The contemporary management of systemic sclerosis

References

• Pellar RE, Pope JE. Evidence-based management of systemic sclerosis: navigating recommendations and guidelines. Semin Arthritis Rheum. 2017;46:767–774.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Pope JE. Emerging drugs and therapeutics for systemic sclerosis. Expert Opin Emerg Drugs [Internet]. 2016;21:421–430.
   PubMed Web of Science ®Google Scholar
• Herrick AL, Pan X, Peytrignet S, et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann Rheum Dis. 2017;76:1207–1218.
   PubMed Web of Science ®Google Scholar
• Desbois AC, Cacoub P. Systemic sclerosis: an update in 2016. Autoimmun Rev. 2016;15:417–426.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327–1339.
   PubMed Web of Science ®Google Scholar
• Lee JJ, Pope JE. Diagnosis and management of systemic sclerosis: a practical approach. Drugs. 2016;76:203–213.
   PubMed Web of Science ®Google Scholar
• Poormoghim H, Lakeh MM, Mohammadipour M, et al. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int. 2012;32:2431–2444.
   PubMed Web of Science ®Google Scholar
• Breuckmann F, Gambichler T, Altmeyer P, et al. UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review. BMC Dermatol. 2004;4:1–14.
   PubMedGoogle Scholar
• Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44:1351–1358.
   PubMed Web of Science ®Google Scholar
• Sanges S, Guerrier T, Launay D, et al. Role of B cells in the pathogenesis of systemic sclerosis. Rev Med Interne. 2017;38:113–124.
   PubMed Web of Science ®Google Scholar
• Walecka I. Systemic sclerosis and the gastrointestinal tract. Gastroenterol Rev. 2017;3:163–168.
   Google Scholar
• Foocharoen C, Chunlertrith K, Mairiang P, et al. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology (Oxford). 2017;56:214–222.
   PubMed Web of Science ®Google Scholar
• Al-Dhaher FF, Pope JE, Ouimet JM. Determinants of morbidity and mortality of systemic sclerosis in Canada. Semin Arthritis Rheum. 2010;39:269–277.
   PubMed Web of Science ®Google Scholar
• Burt RK, Milanetti F. Hematopoietic stem cell transplantation for systemic sclerosis. Curr Opin Rheumatol. 2011;23:519–529.
   PubMed Web of Science ®Google Scholar
• Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology. 2016;55:1906–1910.
   PubMed Web of Science ®Google Scholar
• Van Den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35:364–372.
   PubMedGoogle Scholar
• Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4:708–719.
   PubMed Web of Science ®Google Scholar
• Barsotti S, Bruni C, Orlandi M, et al. One year in review 2017: systemic sclerosis. Clin Exp Rheumatol. 2017;35:S3–20.
   PubMedGoogle Scholar
• Le EN, Wigley FM, Shah AA, et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis. 2011;70:1104–1107.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med [Internet]. 2006;354:2655–2666.
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP. Treatment of systemic sclerosis-related interstitial lung disease: A review of existing and emerging therapies. Ann Am Thorac Soc. 2016;13:2045–2056.
   PubMed Web of Science ®Google Scholar
• Giuggioli D, Lumetti F, Colaci M, et al. Rituximab in the treatment of patients with systemic sclerosis. Our Experience Review Literature Autoimmun Rev. 2015;14:1072–1078.
   PubMed Web of Science ®Google Scholar
• Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69:193–197.
   PubMed Web of Science ®Google Scholar
• Bosello SL, De Luca G, Rucco M, et al. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis. Semin Arthritis Rheum. 2015;44:428–436.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease. Semin Arthritis Rheum. 2017;46:625–631.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis S-NC, Tsamandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheumatol. 2012;30:S17–S22.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Liossis SNC, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology. 2010;49:271–280.
   PubMed Web of Science ®Google Scholar
• Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60:578–583.
   PubMed Web of Science ®Google Scholar
• Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12:R54.
   PubMed Web of Science ®Google Scholar
• Smith V, Piette Y, Van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40:52–57.
   PubMed Web of Science ®Google Scholar
• Moazedi-Fuerst F, Kielhauser S, Brickmann K, et al. Rituximab for systemic sclerosis: arrest of pulmonary disease progression in five cases Results of a lower dosage and shorter interval regimen. Scand J Rheumatol. 2014;43(3):257–258.
   PubMed Web of Science ®Google Scholar
• Jordan S, Distler JHW, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2015;74:1188–1194.
   PubMed Web of Science ®Google Scholar
• Saunders P, Tsipouri V, Keir GJ, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18:275.
   Google Scholar
• Hassani J, Feldman SR. Phototherapy in scleroderma. Dermatol Ther. 2016;519–553.
   Web of Science ®Google Scholar
• Durand F, Staumont D, Bonnevalle A, et al. Ultraviolet A1 phototherapy for treatment of acrosclerosis in systemic sclerosis: controlled study with half-side comparison analysis. Photodermatol Photoimmunol Photomed. 2007;23:215–221.
   PubMed Web of Science ®Google Scholar
• Kreuter A, Breuckmann F, Uhle A, et al. Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. J Am Acad Dermatol. 2004;50:740–747.
   PubMed Web of Science ®Google Scholar
• Morita A, Kobayashi K, Isomura I, et al. A1 (340–400 nm) phototherapy for scleroderma in systemic sclerosis. J Am Acad Dermatol [Internet]. 2000 Oct [cited 2018 May 22];43(4):670–674. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11004624
   PubMed Web of Science ®Google Scholar
• Usmani N, Murphy A, Veale D, et al. Photochemotherapy for systemic sclerosis: effect on clinical and molecular markers. Clin Exp Dermatol. 2009;35:608–613.
   PubMed Web of Science ®Google Scholar
• Hofer A, Soyer HP. Oral psoralen-UV-A for systemic scleroderma. Arch Dermatol. 1999;135:603–604.
   PubMed Web of Science ®Google Scholar
• Zhou XA, Choi J. Photopheresis: advances and use in systemic sclerosis. Curr Rheumatol Rep. 2017;19:31.
   PubMed Web of Science ®Google Scholar
• Poelman CL, Hummers LK, Wigley FM, et al. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol. 2015;42:236–242.
   PubMed Web of Science ®Google Scholar
• Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31:151–156.
   PubMed Web of Science ®Google Scholar
• Gordon JK, Martyanov V, Franks JM, et al. Belimumab for the treatment of early diffuse systemic sclerosis. Arthritis Rheumatol. 2018;70:308–316.
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP. Treatment of systemic sclerosis-related interstitial lung disease: a review of existing and emerging therapies. Ann Am Thorac Soc. 2016;13:2045–2056.
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II. Arthritis Rheumatol. 2017;69:1451–1460.
   PubMed Web of Science ®Google Scholar
• Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006;54:3962–3970.
   PubMed Web of Science ®Google Scholar
• De Cruz S, Ross D. Lung transplantation in patients with scleroderma. Curr Opin Rheumatol. 2013;25:714–718.
   PubMed Web of Science ®Google Scholar
• Fernández-Codina A, Berastegui C, Pinal-Fernández I, et al. Lung transplantation in systemic sclerosis: a single center cohort study. Jt Bone Spine. 2018;85:79–84.
   PubMed Web of Science ®Google Scholar
• Sottile PD, Iturbe D, Katsumoto TR, et al. Outcomes in systemic sclerosis-related lung disease after lung transplantation. Transpl J. 2013;95:975–980.
   PubMed Web of Science ®Google Scholar
• Crespo MM, Bermudez CA, Dew MA, et al. Lung transplant in patients with scleroderma compared with pulmonary fibrosis. Short- and long-term outcomes. Ann Am Thorac Soc. 2016;13:784–792.
   PubMed Web of Science ®Google Scholar
• Shah RJ, Boin F. Lung transplantation in patients with systemic sclerosis. Curr Rheumatol Rep. 2017;19:5.
   PubMed Web of Science ®Google Scholar
• Galiè N, Humbert M, Vachiery J-L, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2015;2016(37):67–119.
   Google Scholar
• Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809–818.
   PubMed Web of Science ®Google Scholar
• Mihai C, Antic M, Dobrota R, et al. Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Ann Rheum Dis. 2018;77:128–132.
   PubMed Web of Science ®Google Scholar
• Girgis RE, Mathai SC, Krishnan JA, et al. Long-term outcome of Bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Hear Lung Transplant. 2005;24:1626–1631.
   PubMed Web of Science ®Google Scholar
• Badesch DB, McGoon MD, Barst RJ, et al. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous Epoprostenol. J Rheumatol. 2009;36:2244–2249.
   PubMed Web of Science ®Google Scholar
• Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D60–D72.
   PubMed Web of Science ®Google Scholar
• Herrick AL, Van Den Hoogen F, Gabrielli A, et al. Modified-release sildenafil reduces Raynaud’s phenomenon attack frequency in limited cutaneous systemic sclerosis. Arthritis Rheum. 2011;63:775–782.
   PubMed Web of Science ®Google Scholar
• Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis & Rheumatism. 2001;44:1841–1847.
   Google Scholar
• Tingey T, Shu J, Smuczek J, et al. Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res. 2013;65:1460–1471.
   PubMed Web of Science ®Google Scholar
• Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Ann Intern Med. 1994;120:199–206.
   PubMed Web of Science ®Google Scholar
• Roustit M, Blaise S, Allanore Y, et al. Phosphodiesterase-5 inhibitors for the treatment of secondary Raynaud’s phenomenon: systematic review and meta-analysis of randomised trials. Ann Rheum Dis. 2013;72:1696–1699.
   PubMed Web of Science ®Google Scholar
• Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32–38.
   PubMed Web of Science ®Google Scholar
• Vigone B, Caronni M, Severino A, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017;19:1–8.
   PubMed Web of Science ®Google Scholar
• Frech TM, Mar D. Gastrointestinal and hepatic disease in systemic sclerosis. Rheum Dis Clin North Am. 2018;44:15–28.
   PubMed Web of Science ®Google Scholar
• Richard N, Hudson M, Gyger G, et al. Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. Rheumatol (United Kingdom). 2017;56:581–588.
   PubMed Web of Science ®Google Scholar
• Ariyasu H, Iwakura H, Yukawa N, et al. Clinical effects of ghrelin on gastrointestinal involvement in patients with systemic sclerosis. Endocr J. 2014;61:735–742.
   PubMed Web of Science ®Google Scholar
• Muangchan C, Markland J, Robinson D, et al. The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis a systematic review. J Rheumatol. 2013;40:1545–1556.
   PubMed Web of Science ®Google Scholar
• Turk M, Pope JE. The frequency of scleroderma renal crisis over time: a metaanalysis. J Rheumatol. 2016;43:1350–1355.
   PubMed Web of Science ®Google Scholar
• Baron M, Pope J, Robinson D, et al. Calcinosis is associated with digital ischaemia in systemic sclerosis – a longitudinal study. Rheumatol (United Kingdom). 2016;55:2148–2155.
   PubMed Web of Science ®Google Scholar
• Young A, Namas R, Dodge C, et al. Hand impairment in systemic sclerosis: various manifestations and currently available treatment. Curr Treat Options Rheumatol. 2016;2:252–269.
   PubMedGoogle Scholar
• Rannou F, Boutron I, Mouthon L, et al. Personalized physical therapy versus usual care for patients with systemic sclerosis: a randomized controlled trial. Arthritis Care Res (Hoboken). 2017;69:1050–1059.
   PubMed Web of Science ®Google Scholar
• Van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA J Am Med Assoc. 2014;311:2490–2498.
   PubMed Web of Science ®Google Scholar
• Burt RK, Shah SJ, Dill K, et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet. 2011;378:498–506.
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N Engl J Med. 2018;378:35–47.
   PubMed Web of Science ®Google Scholar
• Khanna D, Denton CP, Jahreis A, et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet. 2016;387:2630–2640.
   PubMed Web of Science ®Google Scholar
• De Paoli FV, Nielsen BD, Rasmussen F, et al. Abatacept induces clinical improvement in patients with severe systemic sclerosis. Scand J Rheumatol. 2014;43:342–345.
   PubMed Web of Science ®Google Scholar
• Wehner Fage S, Arvesen K, Olesen A. Abatacept improves skin-score and reduces lesions in patients with localized scleroderma: a case series. Acta Derm Venereol. 2018;98:465–466.
   PubMed Web of Science ®Google Scholar
• Distler O, Pope J, Denton C, et al. RISE-SSc: riociguat in diffuse cutaneous systemic sclerosis. Respir Med. 2017;122:S14–S17.
   PubMed Web of Science ®Google Scholar
• Spiera R, Hummers L, Chung L, et al. Oral Presentations. In: OP0126: a phase 2 study of safety and efficacy of anabasum (JBT-101) in systemic sclerosis. BMJ Publishing Group Ltd and European League Against Rheumatism. 2017. Available from: http://dx.doi.org/10.1136/annrheumdis-2017-eular.2712.
   Google Scholar
• Distler O, Brown KK, Distler JHW, et al. Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS™). Clin Exp Rheumatol. 2017;35:75–81.
   PubMed Web of Science ®Google Scholar
• Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J Rheumatol. 2016;43(9):1672–1679.
   PubMed Web of Science ®Google Scholar
• Fraticelli P, Gabrielli B, Pomponio G, et al. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16(4):R144.
   PubMed Web of Science ®Google Scholar
• Pope JE, Lee JJ, Denton CP. Editorial: bench to bedside-and back again: finding the goldilocks zone within the scleroderma universe. Arthritis Rheumatol. 2018;70:155–156.
   PubMed Web of Science ®Google Scholar